Sabby Management’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Sabby Management’s Portfolio NVIV Stock Details NVIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,306	Closed	-$55K	–	143
2020 Q1	$55K	Buy	+1,306	New	+$185K	0.02%	74
2018 Q3	–	Sell	-226	Closed	-$288K	–	160
2018 Q2	$288K	Buy	+226	New	+$1.24M	0.04%	95
2016 Q3	–	Sell	-31	Closed	-$3.87M	–	363
2016 Q2	$3.35M	Buy	31 +2	+7%	+$235K	0.18%	73
2016 Q1	$3.79M	Buy	+29	New	+$3.11M	0.19%	57

Other funds holding NVIV

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sabby Management's NVIV Position: Q2 2020 in Review

Sabby Management sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2020, closing a stake of 1,306 shares — an estimated $55K sold.

Sabby Management first reported a position in NVIV in Q1 2016 and held it in 4 quarters. The position peaked at $3.79M in Q1 2016. 9 funds tracked by Wall St. Rank hold NVIV as of Q2 2020.

Sabby Management reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2020 after selling out during the quarter.
Sabby Management sold 1,306 InVivo Therapeutics Holdings Corp shares in Q2 2020, an estimated $55K.
Sabby Management first reported a position in InVivo Therapeutics Holdings Corp in Q1 2016 and held it in 4 quarters.
Sabby Management's InVivo Therapeutics Holdings Corp position peaked at $3.79M in Q1 2016.
9 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2020.

Based on Sabby Management's 13F filing for Q2 2020, filed 14 Aug 2020.